The Reply - 16/06/22
Doi : 10.1016/j.amjmed.2022.02.027
Salvatore Mangione, MD a, ⁎ 
, Brian F. Mandell, MD, PhD b, c, Stephen G. Post, PhD d
, Brian F. Mandell, MD, PhD b, c, Stephen G. Post, PhD d a Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Penn
b Department of Rheumatology and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio
c Editor-in-Chief, Cleveland Clinic Journal of Medicine, Cleveland, Ohio
d Center for Medical Humanities, Compassionate Care & Bioethics, Stony Brook University School of Medicine, Stony Brook, NY
⁎Requests for reprints should be addressed to Salvatore Mangione, MD, Associate Professor of Medicine, Sidney Kimmel Medical College of Thomas Jefferson University, 1001 Locust Street – Suite 309C, Philadelphia, PA, 19107.Associate Professor of MedicineSidney Kimmel Medical College of Thomas Jefferson University1001 Locust Street – Suite 309CPhiladelphiaPA,19107
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflicts of Interest: None. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
© 2022
Publié par Elsevier Masson SAS.
Vol 135 - N° 7
P. e224 - juillet 2022 Retour au numéro
Article précédent
- Comments on ‘The Language Game’
- Daniel Reinharth
- Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial
- Renato D. Lopes, Patrícia O. Guimarães, Gregory G. Schwartz, Deepak L. Bhatt, Vera A. Bittner, Andrzej Budaj, Anthony J. Dalby, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Robert Gabor Kiss, Megan Loy, Robert Pordy, Yann Poulouin, Michael Szarek, Harvey D. White, Philippe Gabriel Steg, ODYSSEY OUTCOMES Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?